- Trial Phase
- Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- Time to Market
- If the FDA approves on schedule, a U.S. launch could follow within weeks-to-months of the November 2026 PDUFA date; EU decision expected H2 2027, so EU commercialization is further out.
- Why 6/10
- The next hard, dated catalyst is the FDA PDUFA target action date of November 2026 for the cemdisiran NDA in generalized myasthenia gravis (Priority Review) — a dated binary within ~6 months on a significant pipeline asset, but at a ~$73B diversified biotech where cemdisiran is one of many programs, so impactScore sits at 6 (not 8+).
Watch for the FDA decision on the cemdisiran gMG NDA around November 2026 (Priority Review) — an approval would likely add a modest, first-in-class growth asset for REGN rather than a valuation-changing event, given the company's ~$73B market cap is driven mainly by Dupixent/EYLEA/Libtayo. Treat it as a pipeline tailwind, not a standalone thesis; also monitor the fianlimab securities class action (lead-plaintiff deadline September 14, 2026) as a separate overhang.
Price Chart
Executive Summary
Cemdisiran is Regeneron's investigational siRNA therapy targeting complement C5 for generalized myasthenia gravis (gMG). It posted positive Phase 3 NIMBLE results (primary and key secondary endpoints met) and its NDA was accepted by the FDA under Priority Review with a target action date of November 2026; the EMA decision is expected in H2 2027, and it could be the first siRNA approved for gMG with quarterly subcutaneous dosing. SecBot's catalyst records also tag Alnylam (ALNY), the RNAi platform's originator, alongside REGN.
How It Works
Cemdisiran is a small interfering RNA (siRNA) therapy: an injected genetic medicine that silences the gene making complement protein C5, lowering C5 levels and damping the immune-system attack that damages nerve-muscle signaling in generalized myasthenia gravis. It is designed for subcutaneous injection about four times a year, versus more frequent dosing of existing infused therapies.
Trial Status
Phase 3 NIMBLE trial in generalized myasthenia gravis met primary and key secondary endpoints with statistically significant, clinically meaningful results (positive readout announced ~April 2026). Regeneron submitted the U.S. NDA; FDA and EMA accepted the applications, FDA granted Priority Review with target action date November 2026, and an EMA decision is expected in H2 2027.
The Two-Sided Case
Upcoming Catalysts
- FDA PDUFA target action date for cemdisiran in gMG — November 2026 (Priority Review).
- EMA decision on the cemdisiran MAA — expected H2 2027.
- Q3/Q4 2026 earnings calls may include NDA review status updates.
- Separately, REGN's garetosmab PDUFA date was 2026-08-01 and the fianlimab class-action lead-plaintiff deadline is September 14, 2026.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report